Nassif David W. sold $303K of PHVS

Nassif David W. (CFO / CLO) sold 10,000 shares of Pharvaris N.V. (PHVS) at $30.31 ($0.30M total) on 2026-05-21.

Original reporting
SEC EDGAR · Nassif David W.
Published May 26, 2026, 9:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 9:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
medium confidence
Mentioned
$PHVS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

Because the filing contains no company-specific catalyst (no trial result, contract, or regulatory action), the trading signal is primarily sentiment/positioning rather than fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing without additional news.

03

What to watch

Absence of a 10b5-1 plan increases interpretive noise; traders should check for prior/ongoing insider sale patterns and concurrent clinical/regulatory catalysts.

Relevance 6/10Timing: Filed 2026-05-26 for a trade dated 2026-05-21; any market digestion likely occurs around filing/after-hours.

Background

The article is a SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS), reporting an officer/direct sale.

Company-level read

Ticker impact

$PHVSNeutralMedium confidence
Context

Pharvaris CFO/CLO Nassif David W. filed an open-market sale of 10,000 PHVS shares for ~$303K on 2026-05-21.

Expected impact

Likely limited near-term impact; any reaction may be modest and short-lived unless followed by broader insider selling or fundamentals news.

Evidence & confidence

Form 4 insider transactions can signal sentiment, but the article provides only a single sale size and no accompanying operational/clinical/regulatory update.

Market effects

Minimal; insider Form 4 filings rarely reset sector expectations for biotech unless part of a pattern.

Minimal; disclosure is US SEC EDGAR with no stated cross-border event.

Minimal; no international deal/regulatory/clinical milestone is mentioned.

Counterpoint

The sale could be routine liquidity/portfolio management rather than a negative view, especially with only one disclosed transaction.

Key entities

  • PHVS

    Pharvaris N.V., the company whose shares were sold by an officer.

  • Nassif David W.

    CFO/CLO who sold 10,000 PHVS shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.